Effects of continuous positive airway pressure on elderly patients with obstructive sleep apnea: a meta-analysis

Binhong Yan1#, Yongmei Jin2#, Yi Hu1, Shu Li1

Objective: the aim of the study was to evaluate the efficacy of continuous positive airway pressure (CPAP) for the treatment of obstructive sleep apnea in the elderly.

Method: a comprehensive search for qualified clinical trials was performed on April, 2016. Basic demographic information of enrolled subjects, study design, survival rate, cardiovascular events, quality of life scores, and neurocognitive data were extracted for analysis.

Results: A total of seven clinical trials were included in this meta-analysis, in which untreated elderly patients exhibited worse survival rate than those with CPAP (OR=2.22, 95% CI=1.64 to 3.01, P< 0.00001). Treated elderly patients exhibited less cardiovascular risk than those without CPAP (RR=0.49, 95% CI=0.36 to 0.66, P<0.00001) and a statistically significant improvement on all the domains of Quebec Sleepiness Questionnaire, supported by pooled weighted mean difference. Furthermore, CPAP treatment partially improved the cognitive functions.

Conclusion: CPAP treatment achieves improvements in decreasing mortality and controlling cardiovascular events and exhibits few effects on neurocognitive function. Further large-scale, well-designed interventional investigation is needed.

Key words: Elderly, OSA, CPAP, CVD, Cognition, Meta-analysis.

Introduction

Obstructive sleep apnea (OSA) is a chronic disease characterized by common sleep-related respiratory disorder, affecting up to 20% of the general population [1, 2]. The clinical manifestations of sleep apnea are not often obvious, but OSA is highly prevalent among the elderly; it affects 30% to 80% of people over 65 years old [1, 3]. The long-term OSA can result in severe daytime sleepiness, reduced social functioning and quality of life, and increased risk of traffic accidents [4–6], whereas the short-term sequelae are associated with traffic and workplace accidents [7, 8]. Accumulating studies document that OSA can lead to oxidative stress [9], systemic inflammation [10], endothelial dysfunction [11], high blood pressure [12], increased risk of cardiovascular disease [13, 14], stroke [15], and neurocognitive dysfunction [16]. In the elderly (age > 60 years), the prevalence of OSA syndrome is increased and the symptoms can be conflated with the functional impairments of ageing [17]. Takama and Kurabayashi [18] reported that the presence of OSA is a strong predictor of fatal cardiovascular events in elderly patients with cardiovascular disease (CVD). Martinez-Garcia et al. [19] reported that untreated, severe OSA in elderly patients is associated with an approximately two-fold increase in cardiovascular mortality compared with elderly patients without OSA. Continuous positive airway pressure (CPAP) is established as the first-line standard therapy for OSA, which is the most cost-effective treatment for severe or symptomatic forms of OSA [20]. Recent research has shown beneficial effects from CPAP treatment, such as resolving disordered breathing during sleep, normalizing oxygen saturation, and improving nocturnal and daytime symptoms. Moreover, CPAP treatment has demonstrated a positive effect on blood pressure levels [21], and...
significantly decreased cardiovascular complications, including the incidence of hypertension, coronary artery disease, and chronic heart failure, arrhythmia, stroke, and aortic dissection in patients with moderate to severe OSA and CVD [5, 22-24]. CPAP improves cognitive difficulties and reverses brain changes. Recently, several prospectively and retrospectively randomized clinical trials were performed to evaluate the efficacy of CPAP in elderly with OSA compared with those not treated with CPAP. Some studies estimated the overall survival and cardiovascular risk, whereas others validated the neurocognitive function. In this context, a meta-analysis is urgent needed to confirm whether CPAP can treat OSA among the elderly.

Methods

Searching design
The following Mesh terms and keywords on “obstructive sleep apnea,” “continuous positive airway pressure,” and “elderly” were systematically searched through the database PubMed on April 10, 2016. We restricted the published language to English and the published year from 1 January 2000 to the present. In addition, the reference lists of previously published review articles were manually searched.

Inclusion criteria
Eligible references were selected carefully based on the following criteria: (1) the age of enrolled patients was >65 years old; (2) patients with historically or newly diagnosed moderate to severe OSA; (3) studies comparing the clinical outcomes between the CPAP treated and untreated groups; (4) information collected including survival rate, CVD risk rate, cognitive function, sleepiness score, and quality of life, along with the 95% confidential indexes (CIs).

Data extraction and bias assessment
Two reviewers independently extracted all the data with the use of standardized data-abstraction forms. Disagreements were resolved by consensus. The following information was collected from each study, although some information was not contained in some trials: trial name, first author, year of publication, number of patients enrolled in each trial, patient characteristics (including median age, gender, smoking history, OSA severity, and disease history), study design (blinded or not), and outcomes. Outcomes included survival rate, CVD risk rate, and their 95% CIs, as well as cognitive function (such as episodic, short-term memory, and executive function) and quality of life (Quebec Sleep Questionnaire).

The risk of bias of the included studies was assessed from six domains including sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other issues.

Statistical analysis
All the analysis was performed in RevMan 5.3 software. The pooled odds ratios (ORs) for survival rate and pooled risk ratios (RRs) for CVD risk rate were calculated. The weighted mean difference was used to evaluate the effect of CPAP on the quality of life and neurocognitive test. The statistical heterogeneity between trials was evaluated by the chi-squared Q-test based on the fixed-effect model. When the P value of the Q-test was less than 0.1, or when I² was greater than 50%, this result represented heterogeneity between clinical trials. Then, a random effect model was used to accommodate the heterogeneity.

Results

Searching results and Studies enrollment
After systematic database searched and manual review of reference lists in the eligible studies, a total of 34 publications were preliminarily included. On the basis of the selection criteria, seven clinical trials comparing the clinical outcomes, cognitive function, and quality of life between treated and untreated CPAP were included in the present meta-analysis [19, 25-30]. The flow of this search strategy is shown in Figure 1.

Figure 1. Searching diagram and inclusion flowchart.
In this pooled analysis, treated elderly patients exhibited less cardiovascular risk than those without CPAP (RR = 0.49, 95% CI = 0.36 to 0.66, P<0.00001) (Figure 4).

Sleepiness improvement by CPAP for elderly OSA patients
A total of four studies evaluated the subjective sleepiness by Epworth Sleepiness Scale (ESS) score, and the pooled estimate of effect showed a beneficial effect of CPAP on elderly OSA patients, as assessed by the reduction in ESS scores (weighted mean difference 1.70, 95% CI: 1.11, 2.30, P<0.00001, Figure 5). However, a significant heterogeneity existed, which could not be explained by differences in age, gender ratio, body mass index, study location, the mean number of hours of CPAP per study, or the nature of the control.

Quality of life and neurocognitive function changes after CPAP treatment
Three studies evaluated the effect of CPAP treatment on the quality of life by Québec Sleep Questionnaire (QSQ). Pooled weighted mean difference indicated a statistically significant improvement on all the domains of QSQ (Supplementary Figure 1). However, a significant

### 1.4.1 Diurnal Symptoms

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>CPAP treated</th>
<th>Untreated</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td>6.91</td>
<td>0.54</td>
<td>16</td>
</tr>
<tr>
<td>Martinez-Carras, NLIM</td>
<td>5.4</td>
<td>1.3</td>
<td>115</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>131</td>
<td>244</td>
<td>16.6%</td>
</tr>
<tr>
<td>Heterogeneity, Chi^2 = 2.42, df = 1 (P = 0.12); I^2 = 52%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 2.94 (P = 0.003)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 1.4.2 Nocturnal Symptoms

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>CPAP treated</th>
<th>Untreated</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td>6.19</td>
<td>0.71</td>
<td>16</td>
</tr>
<tr>
<td>Martinez-Carras, NLIM</td>
<td>5.4</td>
<td>1.2</td>
<td>115</td>
</tr>
<tr>
<td>McMillan, NLIM</td>
<td>1.6</td>
<td>1.4</td>
<td>113</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>244</td>
<td>240</td>
<td>16.7%</td>
</tr>
<tr>
<td>Heterogeneity, Chi^2 = 20.85, df = 2 (P &lt; 0.00001); I^2 = 90%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 3.03 (P = 0.002)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 1.4.3 Emotions

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>CPAP treated</th>
<th>Untreated</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td>6.27</td>
<td>0.57</td>
<td>16</td>
</tr>
<tr>
<td>Martinez-Carras, NLIM</td>
<td>5.8</td>
<td>1.2</td>
<td>115</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>131</td>
<td>124</td>
<td>25%</td>
</tr>
<tr>
<td>Heterogeneity, Chi^2 = 3.44, df = 1 (P = 0.06); I^2 = 71%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 2.51 (P = 0.01)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 1.4.4 Social interaction

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>CPAP treated</th>
<th>Untreated</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td>6.72</td>
<td>0.17</td>
<td>16</td>
</tr>
<tr>
<td>Martinez-Carras, NLIM</td>
<td>6.1</td>
<td>1.2</td>
<td>115</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>131</td>
<td>124</td>
<td>21.5%</td>
</tr>
<tr>
<td>Heterogeneity, Chi^2 = 0.00, df = 1 (P = 0.98); I^2 = 0%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 0.07 (P &lt; 0.00001)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for subgroup differences: CHI^2 = 2.11, df = 2 (P = 0.55); I^2 = 0%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total (95% CI) 637 612 100.0% 0.43 [0.30, 0.56]
heterogeneity existed, especially in the domains of diurnal symptoms, nocturnal symptoms, and emotions. The data of neuropsychological and neurocognitive tests were extracted from three studies and calculated as the weighted mean difference in each subgroup, which showed that CPAP treatment improved the cognitive functions including TMT A, TMT B, and semantic fluency tests, whereas CPAP had no effect on the digit span and digit symbol, as well as in the neuropsychological tests (Supplementary Figure 2).

Discussion

Several prior meta-analyses have demonstrated the effects of CPAP in patients with OSA, all of which enrolled middle-aged patients. To date, no meta-analysis was carried out to confirm the influence of CPAP on those elderly patients with OSA. The prevalence of OSA is increased in the elders, especially aging over 70 years. Nevertheless, most of these subjects with OSA refused CPAP treatment, whereas many of them did not appear to have a clear understanding of the health consequences of OSA. Hence, several randomized clinical trials were registered hoping to provide clinical evidences to confirm the efficacy of CPAP in elderly OSA patients. In this situation, we carried out this meta-analysis to validate whether CPAP treatment influences clinical outcomes and quality of life in elderly patients with OSA. This is the first meta-analysis in a specific aged population to our best knowledge.

The main findings of this meta-analysis were that, in elderly patients with moderate to severe sleep apnea, CPAP treatment increased the survival rate. Both Ou et al. [25] and Nishihata et al. [26] compared...
or organ deteriorations, comorbidities are inevitable factors to predict all-cause mortality. Marrone et al. reported that CPAP users had a better survival than non-users among subjects with comorbidities taken alone instead of those without comorbidities [32].

Previous studies described that OSA would result in the cognitive deficits and neuropsychological impairments of executive functions, attention, and working memory among old-aged patients [33, 34]. Prior investigation examined the short-term effect of CPAP treatment on neurocognitive performance in elderly subjects with OSA; the results indicated a modest improvement in the survival rate between the CPAP treatment and untreated groups. Both of these two randomized clinical trials found that the event-free survival rate was significantly decreased in the CPAP treatment group, and the adjusted Kaplan–Meier survival curves exhibited significantly decreased mortality in the CPAP treatment group. Further comparison showed that CVD events were statistically decreased after CPAP treatment. However, only small changes in the total cholesterol and no improvement in blood pressure were detected in the McMillan and colleagues study [31]. Although CVD events are the first predictors of death for these elderly OSA people, Du and his colleagues also pointed out that diabetes might be an independent risk factor for them [25]. Considering that aging is profoundly associated with multiple physical or organ deteriorations, comorbidities are inevitable factors to predict all-cause mortality. Marrone et al. reported that CPAP users had a better survival than non-users among subjects with comorbidities taken alone instead of those without comorbidities [32].

Supplementary Figure 2. Forest plot for neurocognitive test.
used EQ-5Q in the McMillan study; CPAP was shown to improve quality of life both generic and disease specific [31]. To date, only one RCT assessed whether CPAP treatment improved pain tolerance in elderly patients with OSA. It was found that CPAP treatment had an analgesic effect and increased the pain tolerance threshold in the elderly [38]. Currently, pain processing can be interfered by poor sleep and restored sleep. Referred in this meta-analysis, CPAP treatment alleviated sleepiness problems in the value of ESS scores. In this context, our results indicate that CPAP treatment could have more benefits in the elderly patients with OSA suffering from chronic pain.

Some limitations of this meta-analysis need to be discussed. First, the follow-up duration time was inconsistent between included trials. More importantly, the duration time has been supposed to have opposite impact on the clinical outcomes, especially the survival time and neuropsychological performance. Long-term follow-up is encouraged to evaluate the survival rate, increasing the prognosis accuracy, whereas it is a major concern in terms of neuropsychological assessment. The reason is because, during this long follow-up period, neuro-

executive functioning [35]. Afterwards, several well-designed RCTs were conducted in confirming the impact of CPAP on cognitive difficulties and neuropsychological problems among those elderly OSA patients [27, 29, 30]. Pooled weighted mean difference showed that CPAP treatment has partial effect on the cognitive functions evidenced in TMT A, TMT B, and semantic fluency tests, whereas it has no impact on the neuropsychological symptoms, such as depression and anxiety. Dalmases et al. recorded resting-state connectivity alterations associated with CPAP treatment in elderly patients [29]. They showed a significant increase in the intensity of connectivity in the right middle frontal gyrus (rMFG), but no association was seen between cognition and increased connectivity within rMFG. The other two studies reinforce that specific regions, such as the hippocampus or frontal structures affecting memory, attention, and executive functioning, were neuroimaging-scanned showing structure alterations associated with cognitive function improvements in CPAP treated subjects [36, 37]. Nevertheless, their work shows new insight into the effect of CPAP on brain function and structure changes among elderly patients with OSA, as well as in the context of aging.

From the standpoint of quality of life, two kinds of measurements, QSQ and the European Quality of Life-5 Dimensions (EQ-5D), were applied in the included RCTs. CPAP treatment improves the quality of life measured by QSQ, including day-time and night-time symptoms and social and emotional domains. However, only one study used EQ-5Q in the McMillan study; CPAP was shown to improve quality of life both generic and disease specific [31]. To date, only one RCT assessed whether CPAP treatment improved pain tolerance in elderly patients with OSA. It was found that CPAP treatment had an analgesic effect and increased the pain tolerance threshold in the elderly [38]. Currently, pain processing can be interfered by poor sleep and restored sleep. Referred in this meta-analysis, CPAP treatment alleviated sleepiness problems in the value of ESS scores. In this context, our results indicate that CPAP treatment could have more benefits in the elderly patients with OSA suffering from chronic pain.

Some limitations of this meta-analysis need to be discussed. First, the follow-up duration time was inconsistent between included trials. More importantly, the duration time has been supposed to have opposite impact on the clinical outcomes, especially the survival time and neuropsychological performance. Long-term follow-up is encouraged to evaluate the survival rate, increasing the prognosis accuracy, whereas it is a major concern in terms of neuropsychological assessment. The reason is because, during this long follow-up period, neuro-
logical modifications cannot be easily ignored and not because of another pathophysiological process considering the physical specialty of the elderly population. Also, there was a concern about i) a possible blinding bias, ii) that CPAP was a physical device and that no sham CPAP was used in the control group among enrolled RCTs, which needs a strict design and performance to exclude the placebo bias. Finally, cognitive and neuropsychological tests were inconsistently performed in the enrolled RCTs.

In conclusion, OSA should be widely accepted as an independent risk factor for the elderly population, and OSA has profound healthy effects leading to multiple comorbidities. CPAP treatment for the elderly patients with OSA achieves improvements in the event-free survival rate and the occurrence of CVD events. Further large-scale, well-designed RCTs are needed to confirm the CPAP influence in the context of comorbidities associated with aging problem, as well as the cognitive performance and neuropsychological impairments.

**FUNDING**
Pu-dong Health Bureau of Shanghai provided financial support in the form of key discipline construction project. The sponsor had no role in the design or conduct of this research.

**CONFLICT OF INTEREST**
All authors claimed no conflict of interest.

**ETHICAL APPROVAL**
All procedures performed in studies involving human participants were in accordance with the ethical standards of the research committee of Shanghai Seventh People’s hospital and with the 1964 Helsinki declaration and its later amendments.

**INFORMED CONSENT**
Informed consent was obtained from all individual participants included in this study.

**REFERENCES**

REFERENCES


